falsefalse

New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices - Episode 4

Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population

, , ,

Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning
    EP. 2: Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
    EP. 3: Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies
    Now Viewing
    EP. 4: Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population
    EP. 5: Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study
    EP. 6: Panel Discuses Use of CD19 Bispecifics in Sequencing
    EP. 7: Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion
    EP. 8: Current Approach to Bridging Therapy in R/R DLBCL
    EP. 9: Risk of Secondary Malignancies in Heavily Pre-Treated Population
    EP. 10: Management of CRS and ICANS with CAR T-cell Therapy
    EP. 11: Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line
    EP. 12: Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy
    EP. 13: Bispecific therapy – treatment setting and management of short-term adverse events
    EP. 14: Bispecific therapy – management of long-term adverse events in the community setting
    EP. 15: Practice Patterns and Real Use of Epcoritamab and Glofitamab
    EP. 16: Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

    Video content above is prompted by the following:

    • Please discuss the data for 2L treatment with CAR T-cell therapy for patients who are transplant-ineligible.
      • Do the defining characteristics of transplant-ineligible used in the following studies reflect which patients are considered transplant-ineligible in the real world?
      • ALYCANTE- Phase 2 trial.
      • PILOT – Phase 2 trial.
      • What are some key takeaways from the results of these two studies?
    x